CareCloud
CareCloud's revenue rose 8.7% to $120 million in fiscal 2025. Its operating margin was 9.4%, up from 8.2% a year earlier. Free cash flow was $24 million, up 25.5%. The diluted share count rose 135.1%.
Operating margin is operating income as a share of revenue. Free cash flow is cash from operations minus capital spending. Return on capital is after-tax operating income as a share of the money invested in the business: debt plus equity, minus cash. Market cap is the last closing share price times the latest diluted share count, so it is approximate. P/E is the last close divided by diluted earnings per share over the last four quarters, or the latest fiscal year where the quarters aren't available; there is none when the company made a loss.
Charts show fiscal years, from the 10-K filings.
What CareCloud does
CareCloud sells software and back-office services to US doctors' practices, medical groups, hospitals and health systems. Its main service is revenue cycle management: handling a provider's medical billing, coding and insurance claims so it gets paid. It also sells cloud-based electronic health records and practice management software, tools that use artificial intelligence to draft insurance appeals and answer patient calls, remote patient monitoring and telemedicine, and IT consulting and temporary staff for health systems.
It reports two segments. Healthcare IT holds the billing services, usually charged as a percentage of the payments a client collects, with the client's use of CareCloud's software included in the fee; these accounted for about 63% of revenue in 2025. Medical Practice Management, where CareCloud runs practices' offices, staff and supplies for a fee, brought in about 12%. It competes with other billing, practice management and health records providers, including regional billing firms, and with large health systems that do this work themselves.
Most of its work, from software development to customer support and billing, is done by about 3,300 employees in offices abroad, about 98% of them in Pakistan and the rest in Sri Lanka. CareCloud has grown by buying other companies, recently including Medsphere, MAP App and RevNu Medical Management.
Its biggest risks, as it describes them
- Its reliance on its offices in Pakistan, where unrest, sanctions or other disruptions could raise its costs or stop its work.
- Software or service platforms, including ones it bought, failing to work properly, which could bring claims or cost it clients.
- Failing to keep the clients and revenue of the businesses it buys, or to integrate them well.
- Strong competition, including from large health systems that bring billing work in-house.
- Breaking the many healthcare, privacy and billing laws that apply to its work for providers.
Income statement
Returns on capital
Balance sheet
Five years at a glance
| Fiscal year end | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|
| Cash and short-term investments | 9 | 12 | 3 | 5 | 3 |
| Debt incl. finance leases | 9 | 9 | 11 | 1 | 2 |
| Net debt (negative means net cash) | −1 | −4 | 7 | −4 | −1 |
| Net debt to EBITDA | −0.0x | −0.2x | — | −0.2x | −0.1x |
| Debt to equity | 0.1x | 0.1x | 0.2x | 0.0x | 0.0x |
| Interest coverage | 34.3x | 40.8x | −50.8x | 13.5x | 50.2x |
| Current ratio | 1.2x | 1.6x | 1.0x | 1.3x | 1.1x |
| Quick ratio | 1.2x | 1.5x | 1.0x | 1.2x | 1.0x |
Cash flow
Projections
Project CareCloud's revenue, net income and earnings per share five years ahead in a bull, a base and a bear case with your own figures, and see the share prices your P/E estimates give them, or value it with a discounted cash flow model. Every projected figure is yours: it is not a forecast of ours.
What CareCloud says to expect
- Calendar year 2026: GAAP earnings per share
GAAP EPS guidance of $0.20–$0.23 represents a 100-130% increase from the $0.10 achieved in full year 2025.
- Calendar year 2026: adjusted EBITDA
Adjusted EBITDA guidance of $29–$31 million represents growth of approximately 5–13% over 2025 actuals of $27.5 million.
Insider trades
No officer, director or 10% owner of CareCloud reported buying or selling its shares on the open market between November 20, 2025 and November 19, 2026.
Indicators
Four widely used measures, worked out from the company's filings. The cutoffs are the ones their authors or users go by, not a verdict of ours.
| Indicator | FY23 | FY24 | FY25 |
|---|---|---|---|
| Piotroski F-score | 2 of 8 | 7 of 8 | 5 of 8 |
| Rule of 40 | −5.1% | 11.8% | 28.4% |
| Altman Z'' | −5.98 | 0.69 | 1.11 |
| Accruals ratio | −59.9% | −17.1% | −22.3% |
The nine F-score tests
| Test | FY23 | FY24 | FY25 |
|---|---|---|---|
| Net income is positive | Fail | Pass | Pass |
| Cash from operations is positive | Pass | Pass | Pass |
| Return on assets rose | Fail | Pass | Pass |
| Cash from operations exceeds net income | Pass | Pass | Pass |
| Debt fell relative to assets | Fail | Pass | Fail |
| Current ratio rose | Fail | Pass | Fail |
| Share count didn't rise | Fail | Fail | Fail |
| Gross margin rose | — | — | — |
| Revenue rose relative to assets | Fail | Pass | Pass |
| F-score | 2 of 8 | 7 of 8 | 5 of 8 |
Compare
Put CareCloud side by side with any other company we cover: revenue, growth, margins, cash flow and returns, with ten years of charts.
Similar companies
| Company | Year | Revenue growth | Operating margin | Free cash flow margin | Return on capital | Net debt to EBITDA | F-score | Compare |
|---|---|---|---|---|---|---|---|---|
| CareCloud | FY25 | 8.7% | 9.4% | 19.7% | 21.5% | −0.1x | 5 | |
| OptimizeRx | FY25 | 18.8% | 10.7% | 17.1% | 6.4% | 0.2x | 8 | Compare |
| NRC Health | FY25 | −4.0% | 16.4% | 11.5% | 16.4% | 2.5x | 5 | Compare |
| HeartFlow | FY25 | 39.9% | −36.4% | −33.5% | — | — | — | Compare |
| SOPHiA GENETICS | FY25 | 18.6% | −91.8% | −47.2% | −207.1% | — | 2 | Compare |
10 years of figures
| Fiscal year | FY16 | FY17 | FY18 | FY19 | FY20 | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|---|---|---|---|---|
| Income statement | ||||||||||
| Revenue | 24 | 32 | 50 | 64 | 105 | 140 | 139 | 117 | 111 | 120 |
| Revenue growth | 6.1% | 29.9% | 58.9% | 27.5% | 63.1% | 32.8% | −0.6% | −15.7% | −5.3% | 8.7% |
| Gross profit | — | — | — | — | — | — | — | — | — | — |
| Research and development | 1 | 1 | 1 | 1 | 9 | 4 | 4 | 5 | 4 | 6 |
| Operating income | −8 | −4 | −2 | 0 | −8 | 4 | 7 | −47 | 9 | 11 |
| Net income | −9 | −6 | −2 | −1 | −9 | 3 | 5 | −49 | 8 | 11 |
| Diluted EPS (US$) | −0.95 | −0.69 | −0.59 | −0.60 | −1.79 | −0.77 | −0.67 | −4.11 | −0.28 | 0.10 |
| Diluted shares (millions) | 10 | 11 | 12 | 12 | 13 | 14 | 15 | 16 | 16 | 38 |
| Cash flow | ||||||||||
| Cash from operations | −1 | 0 | 7 | 8 | −1 | 13 | 21 | 16 | 21 | 29 |
| Capital expenditure | 0 | 1 | 1 | 2 | 3 | 3 | 3 | 3 | 2 | 5 |
| Free cash flow | −1 | −0 | 6 | 6 | −3 | 10 | 19 | 12 | 19 | 24 |
| Dividends paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Share buybacks | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Acquisitions | 3 | 0 | 13 | 2 | 24 | 13 | 0 | 0 | 0 | 16 |
| Stock-based compensation | 2 | 2 | 2 | 3 | 6 | 5 | 5 | 5 | 0 | 0 |
| Balance sheet at fiscal year end | ||||||||||
| Cash and short-term investments | 4 | 4 | 14 | 20 | 21 | 9 | 12 | 3 | 5 | 3 |
| Debt incl. finance leases | 7 | 0 | 1 | 1 | 1 | 9 | 9 | 11 | 1 | 2 |
| Total assets | 28 | 26 | 48 | 56 | 138 | 141 | 136 | 78 | 72 | 88 |
| Total liabilities | 21 | 5 | 9 | 14 | 37 | 43 | 34 | 36 | 22 | 28 |
| Shareholders' equity | 7 | 20 | 39 | 43 | 101 | 98 | 102 | 42 | 50 | 60 |
| Margins and ratios | ||||||||||
| Gross margin | — | — | — | — | — | — | — | — | — | — |
| Operating margin | −32.3% | −14.2% | −5.0% | 0.1% | −7.9% | 2.5% | 4.8% | −40.2% | 8.2% | 9.4% |
| Net margin | −35.9% | −17.5% | −4.2% | −1.4% | −8.4% | 2.0% | 3.9% | −41.6% | 7.1% | 9.0% |
| Free cash flow margin | −5.5% | −1.3% | 11.4% | 8.7% | −3.3% | 7.5% | 13.4% | 10.6% | 17.1% | 19.7% |
| Rule of 40 (growth + FCF margin) | 0.6% | 28.6% | 70.3% | 36.2% | 59.8% | 40.2% | 12.8% | −5.1% | 11.8% | 28.4% |
| Return on capital | −55.5% | −26.8% | −9.7% | 0.2% | −12.5% | 3.8% | 6.5% | −50.6% | 19.0% | 21.5% |
| Return on equity | −80.1% | −40.7% | −7.2% | −2.1% | −12.2% | 2.9% | 5.4% | −67.9% | 17.2% | 19.8% |
| Return on assets | −32.0% | −20.7% | −5.8% | −1.7% | −9.1% | 2.0% | 3.9% | −45.5% | 10.5% | 13.6% |
| Net debt to EBITDA | — | — | −43.6x | −6.3x | −12.3x | −0.0x | −0.2x | — | −0.2x | −0.1x |